Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia

Front-line treatment combining All-trans retinoic acid (ATRA) and chemotherapy is curative in approximately 80% of patients with acute promyelocytic leukemia (APL). As for patients who relapse after this approach, current guidelines recommend the administration of arsenic trioxide (ATO) with or